A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

NCT00000958 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: MTP-PE/MF59
BIOLOGICAL: Env 2-3

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]